Summary
Profile
Financials
Events
Ownership
Options

Company Info

Industry Biotechnology
Sector Health Technology
Employees 20
CEO Dr. Christopher U. Missling
Address 51 West 52nd Street 7th floor, New York, NY 10019-6163
Phone 1.800.689.3939
Website www.anavex.com

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

Competitors

Company Name 3 Month
%Change
1 Year
%Change
Anavex Life Sciences Corp. -16.96% 300.95%
Hill-Rom Holdings, Inc. 33.65% 80.28%
Bausch Health Cos., Inc. -8.46% 50.32%
United Therapeutics Corp. 9.69% 86.10%
Neurocrine Biosciences, Inc. -1.95% -6.42%

Statement Summary

as of 4:00 ET PM 09/17/2021
Total Assets (MRQ) 166.4 M
Total Liabilities (MRQ) 9.3 M
Shareholders’ Equity (MRQ) 157.1 M
Total Revenue (Annual) n/a
Net Income (Annual) -10.2 M

Earnings And Estimates

as of 4:00 ET PM 09/17/2021

Current Qtr EPS Estimate -0.14
Current FY EPS Estimate -0.53
Long Term EPS Growth Estimate 1.00
Next Expected Earnings Date //

AVXL vs S&P 500

as of 09/17/2021
Relative To
S&P 500
AVXL
4 Weeks n/a n/a
12 Weeks n/a n/a
YTD n/a n/a

Earnings Surprises

as of 4:00 ET PM 09/17/2021
Fiscal Quarter Estimate Actual Surprise
06/2021 -0.13 -0.14 +4.48%
03/2021 -0.13 -0.12 -7.69%
12/2020 -0.11 -0.12 +14.29%
09/2020 -0.13 -0.10 -21.57%
06/2020 -0.14 -0.11 -19.51%
03/2020 -0.16 -0.12 -22.58%
12/2019 -0.14 -0.12 -14.29%
09/2019 -0.15 -0.07 -53.33%

Financial Strength

as of 4:00 ET PM 09/17/2021
Pre-Tax Margin 0.00
Net Margin 0.00
Operating Margin 0.00
Return On Equity -35.37
Return On Assets -32.47
Inventory Turnover (TTM) 0.00
Sales Growth (MRQ) n/a

Ratios

as of 4:00 PM ET 09/17/2021
Price/Earnings (TTM) n/a
Price/Book (MRQ) 8.43
Price/Cash Flow (TTM) 0.00
Book Value (MRQ) 2.09
Quick Ratio (MRQ) 17.95
Current Ratio (MRQ) 17.95
Total Debt/Equity (MRQ) 0.00

Short Interest

as of 1:04 PM ET 09/20/2021
% Short - 0.00%
% Remaining Float - 100.00%
Current Last Month
Short Interest Date n/a n/a
Short Interest Shares 0 0
Short Interest Ratio 0.0 0.0
M Y M Y
Total Assets 0,0.00 0,0.00
Total Liabilities 0,0.00 0,0.00
Total Equity 0,0.00 0,0.00
M Y M Y
Total Revenue 0,0.00 0,0.00
EBT Exc.
Unusual Items
0,0.00 0,0.00
Net Income 0,0.00 0,0.00
M Y M Y
Cash from
Operations
0,0.00 0,0.00
Cash from
Activities
0,0.00 0,0.00
Cash from
Fin. Activities
0,0.00 0,0.00

TOTAL ASSETS

TOTAL LIABILITIES

TOTAL EQUITY

Balance Sheet

M Y
ASSETS
Cash And Equivalents 0,0.00
Receivables 0,0.00
Inventories 0,0.00
Other Current Assets 0,0.00
Total Current Assets 0,0.00
Property, Plant & Equipment, Gross 0,0.00
Accumulated Depreciation & Depletion 0,0.00
Property, Plant & Equipment, Net 0,0.00
Intangibles 0,0.00
Other Non-Current Assets 0,0.00
Total Non-Current Assets 0,0.00
TOTAL ASSETS 0,0.00
Liabilities & Shareholder Equity
Accounts Payable 0,0.00
Short Term Debt 0,0.00
Total Current Liabilities 0,0.00
Long Term Debt 0,0.00
Deferred Income Taxes 0,0.00
Other Non-Current Liabilities 0,0.00
Minority Interest 0,0.00
Total Non-Current Liabilities 0,0.00
Preferred Stock Equity 0,0.00
Common Stock Equity 0,0.00
Common Par 0,0.00
Additional Paid In Capital 0,0.00
Cumulative Translation Adjustment 0,0.00
Retained Earnings 0,0.00
Treasury Stock 0,0.00
Other Equity Adjustments 0,0.00
Total Capitalization 0,0.00
TOTAL EQUITY 0,0.00
TOTAL LIABILITIES & STOCK EQUITY 0,0.00
Total Common Shares Outstanding 0,0.00
Preferred Shares 0,0.00
Treasury Shares 0,0.00
Basic Weighted Shares Outstanding 0,0.00
Diluted Weighted Shares Outstanding 0,0.00
Number Of Employees 0,0.00
Number Of Part-Time Employees 0,0.00

TOTAL REVENUES

EBT Excluding Unusual Items

NET INCOME

Income Statement

M Y
Sales 0,0.00
Cost Of Sales 0,0.00
Gross Operating Profit 0,0.00
Selling, General, And Administrative Expenses 0,0.00
Research & Development 0,0.00
Operating Income Before D & A (EBITDA) 0,0.00
Depreciation & Amortization 0,0.00
Interest Income 0,0.00
Other Income - Net 0,0.00
Special Income / Charges 0,0.00
Total Income Before Interest Expenses (EBIT) 0,0.00
Interest Expense 0,0.00
Pre-Tax Income 0,0.00
Income Taxes 0,0.00
Minority Interest 0,0.00
Net Income From Continuing Operations 0,0.00
Net Income From Discontinued Operations 0,0.00
Net Income From Total Operations 0,0.00
Extraordinary Income/Losses 0,0.00
Income From Cum. Effect Of Acct. Change 0,0.00
Income From Tax Loss Carryforward 0,0.00
Other Gains / Losses 0,0.00
Total Net Income 0,0.00
Normalized Income
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
0,0.00
Preferred Dividends 0,0.00
Net Income Available To Common 0,0.00
Basic EPS From Continuing Ops. 0,0.00
Basic EPS From Discontinued Ops. 0,0.00
Basic EPS From Total Operations 0,0.00
Basic EPS From Extraordinary Inc. 0,0.00
Basic EPS From Cum Effect Of Accounting Change 0,0.00
Basic EPS From Tax Loss Carryf'd. 0,0.00
Basic EPS From Other Gains (Losses) 0,0.00
Basic EPS, Total 0,0.00
Basic Normalized Net Income/Share 0,0.00
EPS From Continuing Ops. 0,0.00
EPS From Discontinued Ops 0,0.00
EPS From Total Ops. 0,0.00
EPS From Extraord. Inc. 0,0.00
EPS From Cum Effect of Accounting Change 0,0.00
EPS From Tax Loss Carfd. 0,0.00
EPS From Other Gains (L) 0,0.00
EPS, Total 0,0.00
Diluted Normalized Net Inc/Shr
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
0,0.00
Dividends Paid Per Share 0,0.00

CASH FROM OPERATIONS

CASH FROM INVESTING ACTIVITIES

CASH FROM FINANCING ACTIVITIES

Cash Flow Statement

M Y
Cash Flow From Operating Activities
Net Income (Loss) 0,0.00
Operating Gains/Losses 0,0.00
Gross Operating Profit 0,0.00
(Increase) Decrease In Receivables 0,0.00
(Increase) Decrease In Inventories 0,0.00
(Increase) Decrease In Other Current Assets 0,0.00
(Decrease) Increase In Other Current Liabilities 0,0.00
(Increase) Decrease In Other Working Capital 0,0.00
Other Non-Cash Items 0,0.00
Net Cash From Continuing Operations 0,0.00
Net Cash From Discontinued Operations 0,0.00
Cash Provided By Investing Activities
Net Cash From Total Operating Activities 0,0.00
Sale Of Property, Plant & Equipment 0,0.00
Cash Used For Investing Activities
Sale Of Short-Term Investments 0,0.00
Purchases Of Property, Plant & Equipment 0,0.00
Acquisitions 0,0.00
Purchases Of Short-Term Investments 0,0.00
Other Cash From Investing Activities 0,0.00
Cash Provided by Financing Activities
Net Cash From Investing Activities 0,0.00
Issuance Of Debt 0,0.00
Cash Used For Financing Activities
Issuance Of Capital Stock 0,0.00
Repayment Of Long-Term Debt 0,0.00
Repurchase Of Capital Stock 0,0.00
Payment Of Cash Dividends 0,0.00
Other Financing Charges, Net 0,0.00
Net Cash From Financing Activities 0,0.00
Effect Of Exchange Rate Changes 0,0.00
Net Change In Cash & Cash Equivalents 0,0.00

Earnings Estimates

as of 4:00 ET PM 09/17/2021
Current Qtr
(09/2021)
Next Qtr
(12/2021)
Consensus Estimate $-0.14 $-0.14
# of Estimates 5 2
High Estimate $-0.12 $-0.13
Low Estimate $-0.17 $-0.14
Year Ago EPS $-0.10 $-0.12
Year Over Year Growth Estimate 47.39% 10.47%
Current Yr
(09/2021)
Next Yr
(09/2022)
Consensus Estimate $-0.53 $-0.61
# of Estimates 5 5
High Estimate $-0.48 $-0.45
Low Estimate $-0.55 $-0.86
Year Ago EPS $-0.45 $-0.53
Year Over Year Growth Estimate 16.89% 16.35%
Current Qtr
(09/2021)
Next Qtr
(12/2021)
Current Year
(09/2021)
Next Year
(09/2022)
Consensus Estimate $-0.14 $-0.14 $-0.53 $-0.61
# of Estimates 5 2 5 5
High Estimate $-0.12 $-0.13 $-0.48 $-0.45
Low Estimate $-0.17 $-0.14 $-0.55 $-0.86
Year Ago EPS $-0.10 $-0.12 $-0.45 $-0.53
Year Over Year Growth Estimate 47.39% 10.47% 16.89% 16.35%

Insider Information Summary

as of 08/31/2021
% Insiders - 3.10%
% Remaining Total Shares - 96.90%
Current 1 Month
Net Insider Transaction 0.00 1.00 K
Shares Bought 218.32 K 364.32 K
Shares Sold 218.32 K 363.32 K

Insider Activity

Transaction Date Insider/Title Transaction Type Market Value Shares Average Price Current Holdings

LATEST NEWS

Recent Articles from TheStreet

Bitcoin Down Lead

Bitcoin Gets Blasted, But Should You Buy the Dip or Wait?

Bitcoin prices are getting smashed on Monday. So far support is holding, but is it dependable enough to buy? Let's look at the chart.

Nasdaq-listed Chinese Electric Carmaker Li Auto Apologises For Passing Off Recall Of 10,469 Li ONEs As 'upgrade' Offer

Chinese EV Maker Li Cuts Delivery Forecast, Shares Fall

Li trims its forecast to 24,500 vehicle deliveries for the third quarter from 25,000 to 26,000.

Toys 'R' Us Sells FAO Schwarz as it Reveals Further Debt Refinancing Plans

Toymakers Facing Holiday Challenge Due to Supply-Chain Issues

Supply-chain issues could make this Christmas season more challenging than normal for toymakers, a media report says.

AstraZeneca Takeover Chatter Bubbles Up Again After Massive Drug Trial Disappointment

AstraZeneca Stock Rises on Progress With Breast-Cancer Treatment

AstraZeneca's breast-cancer treatment reduced the risk of disease progression or death by 72% vs. a currently approved treatment.

Twitter Blue Lead

Twitter to Pay $810M to Settle Holder Suit Over User Engagement

Twitter's payment would settle a shareholder lawsuit that the company misled investors about its user engagement totals.

Starboard Takes Stake in CVS Health Corp.: Report

CVS to Add 25,000 Workers Ahead of Flu Season, Covid Booster Shots

Pharmacy giant CVS plans to add 25,000 ahead of flu season and coronavirus-related vaccinations.

Chinese Investors Mock Asset Managers And Offer Advice On Stock Picks For Cautious Approach To Renewables Sector

Stocks May Drop 20% as Stimulus Eases, Growth Slows: Morgan Stanley

Stocks could drop 20% as fiscal stimulus is withdrawn and economic growth slows, a Morgan Stanley strategist says.

Cryptocurrency Lead

Cryptocurrency Price Check: Bitcoin Tumbles on Evergrande Woes

Bitcoin and other cryptocurrencies are battered as China Evergrande Group struggles with bond obligations.

China Aims To Strengthen Its Semiconductor Supply Chain With New Standards Group That Includes Huawei, SMIC

Brooks Automation Stock Jumps on Plan to Sell Chip Solutions Unit for $3B

Brooks Automation is selling its chip solutions group and said it would no longer pursue splitting into two companies.

DR Horton, Verizon, HCA Holdings Top Analysts' Actions Monday

DR Horton Trims 2021 Sales Forecast Amid Supply Chain Disruptions

DR Horton said "significant disruptions in the supply chain ... along with tightness in the labor market" will lead to a modestly lower full-year sales forecast.